Conference Day 2 - November 8, 2017 

Day Two

08:50

Chairman's opening remarks

STAKEHOLDER ENGAGEMENT

Nazneen Aziz
09:00

The role of biobanks in propelling precision medicine

  •     How Kaiser Permanente implemented precision medicine within its existing nationwide healthcare system
  •     Advancing precision medicine through biobanks with research ready biospecimens and associated EMR data
Panel discussion
09:20

PANEL SESSION: Pricing and reimbursement: guaranteeing market access for precision drugs

  •     Collaborating with payers in order to ensure cost containment in personalized health does not affect expanded patient access
  •     Optimizing value propositions to allay payer and provider scepticism around the cost-benefit balance of precision medicine 
  •     The role of pharmacy benefit managers and pay-for-play programs in precision medicine pathways 
10:00

Platinum Sponsorship Available

Do you have a solution that you would like to share with our audience?
Contact Mike Shackil on +1.646.619.1809 or email: michael.shackil@terrapinn.com
 

10:20 SPEED NETWORKING

10:40 NETWORKING COFFEE BREAK

MANUFACTURING

BIG DATA

Discovery & Development
11:20

The next wave of gene editing in a multi-stakeholder environment

  •     Circumventing ethical concerns around gene editing of early human cells
  •     Payers: Will insurance companies pay for personalized gene editing, and where funding will come from if not 
  •     Alternate uses for CRISPR: controlling genes rather than editing them 
Diagnostics & Data
11:20

More than a match for cancer: outcomes and developments of the NCI’s MATCH program

  •     Hear how the NCI has developed a manageable strategy for patient recruitment in the MATCH program
  •     An analysis of the quid pro quo needed to build collaboration between the NCI and the pharmaceutical industry 
  •     Why the program aims for a 25% rate of rare cancers in patient recruitment and what results this has yielded 
Discovery & Development
11:40

Supporting immunotherapy development with pre-clinical biomarker research

  •     How biomarker discovery teams can work with clinical counterparts for a streamlined development strategy
  •     Modelling biomarker development in the pre-clinical stage of research 
Diagnostics & Data
11:40

My Research Legacy – a project at the intersection of big data, genomics and medicine

  •     Building a platform for millions of patients by curating strategic partnerships in tech
  •     Driving personalized medicine and patient adherence solutions through the AHA’s big data platform 
Discovery & Development
12:00

SPONSORSHIP AVAILABLE

Do you have a solution that you would like to share with our audience?
Contact Mike Shackil on +1.646.619.1809 or email: michael.shackil@terrapinn.com
 
Diagnostics & Data
12:00

SPONSORSHIP AVAILABLE

Do you have a solution that you would like to share with our audience?
Contact Mike Shackil on +1.646.619.1809 or email: michael.shackil@terrapinn.com
 
round tables
12:20

INTERACTIVE ROUNDTABLE DISCUSSIONS

  • Adaptive trials – where companion diagnostics fit in
  • Animal models in pre-clinical biomarker exploration
  • Epigenetics - modifying gene expression and studying the outcomes
  • Finding funding – lobbying for increased federal support for precision medicine
  • Genetic data for drug discovery
  • Human Cell Atlas – discussing the possibilities and pitfalls
  • International data sharing – the obstacles and the opportunities
  • Monica Mallampalli

    Monica Mallampalli, Women's Health & Board of Directors,, SCAD Alliance

  • Medical devices – the interplay between test developer and drug developer
  • Mental health – are genomics enough of a variable?
  • Patient adherence – is it achievable and is it valuable?
  • Prenatal diagnostics – considerations around counselling and education
  • Psychological aspects of genomic screening for patients
  • The Journey to Building a Comprehensive Precision Oncology Program at an Academic Medical Center
  • Bat-ami Katzman Gordon

    Bat-ami Katzman Gordon, Project manager of Precision Medicine at the Sylvester Comprehensive Cancer Center, University of Miami

    13:00

    NETWORKING LUNCH

    INDUSTRY PHARMACOGENOMICS WORKING GROUP
    14:20

    INDUSTRY PHARMACOGENOMICS WORKING GROUP

    Introduction to I-PWG and our intent for the workshop
    In this introduction, we will describe I-PWG, our composition, mission, and goals.  We will describe pharmacogenomics and its importance in drug development, activity within the industry to facilitate the study of pharmacogenomics and the modalities that we leverage to contribute to the development of precision medicines.  
     
    Moderator: Michelle Penny, Senior Director, Head of Computational Biology and Genomics
    Biogen
     
    Talk 1: Optimizing Pharmacogenomics Sampling in Clinical Trials: Current Practices for collecting DNA
    Hear about current solutions within industry, best practices, and challenges to obtaining PGx populations that are representative of the global clinical trial population.

     
    Presenter: Anita Nelsen, Head of Genomic Medicine, PAREXEL International
     
    Talk 2: NGS and its evolving application in pharmacogenomics 
    Learn how companies are utilizing NGS to inform the discovery and development of safe and effective medicine. Data from an I-PWG survey on NGS practices will be shared.
     
    Presenters:  Charles Paulding, Director Pharmacogenomics, Regeneron Pharmaceuticals, Inc. and Denit Oz Levi, Sequencing Analysis & Bioinformatics Expert, Personalized & Predictive Medicine and Big Data Analytics, Teva
     
    Talk 3: Closing the knowledge gap: 
    Pharmacogenomics education and resources for the patient, site staff and ethics committees
    This presentation will highlight the need for pharmacogenomics education and describe some of the resources available through I-PWG.
     
    Presenter: Sandra Prucka, Innovation Lead, Clinical Innovation, Eli Lilly and Company
     
    Panel Discussion- Hot topics
    Presenters TBC
    Anita Head, Sr. Dir and Head, Genomic Medicine, Paraxel International
    Sandra Prucka, Director of Genetic Counseling Clinical Services, Indiana University School of Medicine
    MULTIOMIC DATA
    14:20

    Harnessing patient advocacy in the effort to accelerate precision medicine discovery and development

    •     Rare disease: how the burden is an obstacle to patient engagement and how patient advocacy can overcome it
    •     Patient privacy and how to empower patient advocates and caregivers to champion genomic research
    •     How pharma can build stronger relationships with rare disease and precision medicine foundations 
    MULTIOMIC DATA
    14:40

    Enabling patients to engage with their data

    •     Why offering patient choice leads to increased engagement and adherence with an economic benefit for pharma and physicians
    •     How unprecedented privacy controls in the Reg4All registry allay patient concerns and enable future research
    MULTIOMIC DATA
    15:00

    Multi-omics: integrating multiple data sources into one precision medicine proposal

    •     Combining multiple ‘omics’ into a clear value proposition for patient personalization
    •     Understanding the value of advanced analytical technology in order to integrate data for decision-making processes
    •     Leveraging patient-centered data in a meaningful way by understanding physician needs  
    MULTIOMIC DATA
    15:20

    Wearables for precision medicine

    •     Promoting the use of wearables for acute and chronic illness detection
    •     Collaborating with tech and academia to enable investment from pharma 
    •     Reimbursement: plotting value propositions for companion wearables to fund future advances  
    15:50

    CLOSING REMARKS

    CONFERENCE ENDS

    last published: 22/Sep/17 18:35 GMT